Pertussis: the disease and the vaccine

Area of Science:

• Pediatrics
• Immunology
• Public Health

Background:

• Pertussis (whooping cough) is a severe respiratory illness in infants, posing significant health risks.
• Widespread immunization is crucial for controlling pertussis epidemics, which resurge when vaccination rates decline.
• Whole-cell pertussis vaccines have historically been used due to unidentified immunity-conferring bacterial components.

Purpose of the Study:

• To evaluate the safety and efficacy of whole-cell pertussis vaccination in infants.
• To assess the risk-benefit ratio of pertussis immunization compared to the natural disease.
• To provide guidance on pertussis vaccination for infants with pre-existing neurological conditions.

Main Methods:

• Review of existing studies on whole-cell pertussis vaccine efficacy and adverse events.
• Analysis of the association between vaccination and neurological outcomes, including seizures and brain damage.
• Risk-benefit assessment comparing immunization to the risks of natural pertussis infection.

Main Results:

• Whole-cell pertussis vaccine is effective in preventing disease and infection in some infants.
• Adverse events, such as seizures, are rare and temporary, with permanent brain damage being exceptionally uncommon.
• The risk-benefit ratio favors pertussis immunization, even for infants with static or chronic brain syndromes.

Conclusions:

• Whole-cell pertussis vaccination remains a safe and effective public health strategy.
• Immunization is recommended for most infants, including those with certain neurological conditions.
• Vaccination timing may require adjustment in infants with unclear neurological status.